Most women with breast cancer about to initiate aromatase inhibitors already have bone loss

R. Hernández San Gil,E.M. Rodríguez Rodríguez, L.M. Rodríguez Rodríguez, H. Roldán Delgado,J. Cruz Jurado, M.J. Sánchez Pérez, M.J. de la Vega Prieto, L.S. Medina Vega, M.A. Gómez Rodríguez-Bethencourt,J. Oramas Rodríguez, B.E. Alonso Álvarez, J.N. Batista López

Medicina Clínica Práctica（2021）

引用 0|浏览1

暂无评分

摘要

Women with breast cancer who receive aromatase inhibitors (AI) are at risk of bone mass loss and bone fracture. Many of these women have been previously treated with chemotherapy and/or tamoxifen, also with known deleterious bone effects. We studied the bone mineral status of a group of postmenopausal women with non-advanced breast cancer about to initiate AI treatment.

查看译文

关键词

Breast cancer,Bone mineral density,Vertebral fractures,Aromatase inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要